New Corporate Presentation

N4 Pharma PLC
11 June 2024


N4 Pharma plc

 ("N4 Pharma" or the "Company")


New Corporate Presentation


N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that a new Corporate Presentation has been published.  


The Corporate Presentation can be viewed on the Company's interactive investor hub, at:



For more information please contact:


N4 Pharma plc

Nigel Theobald, CEO

Luke Cairns, Executive Director


SP Angel Corporate Finance LLP

Nominated Adviser and Joint Broker

Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance)

Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

Tel: +44(0)20 3470 0470

Turner Pope Investments (TPI) Limited

Joint Broker

Andy Thacker

James Pope

Tel: +44(0)20 3657 0050


Engage with us by asking questions, watching video summaries and seeing what other shareholders have to say.


About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®.


N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.


For further information on the Company visit or sign up at





This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.


N4 Pharma (N4P)
UK 100

Latest directors dealings